UTv Videos

Kristen R. Scarpato, MD, MPH, discusses what level of evidence is necessary to shift the standard of care in BCG-naive NMIBC.

Amanda C. North, MD, reflects on key takeaways from a panel discussion on imposter syndrome.

Farah Rahman, MD, MPH, highlights a pilot study on the use of wearable biofeedback technology to better understand and address burnout among urology residents.

Regarding acceptable risk thresholds, Alam describes himself as relatively risk-averse, favoring a 5% to 10% miss rate for Grade Group 2 or higher disease when considering biopsy avoidance.

John P. Sfakianos, MD, shares the clinical rationale for the phase 2 ENHANCE trial, evaluating the addition of NKG2A inhibition to PD-1/PD-L1 inhibition in NMIBC.

Aleece Fosnight, MSPAS, PA-C, highlights the importance of tailoring contraceptive choice to symptom patterns.

Veda N. Giri, MD, shares key findings from the PROGRESS Registry, which evaluated patient-reported outcomes with prostate cancer genetic testing.

Pedro F.S. Freitas, MD, recaps his talk at the 2026 Desai Sethi Urology Institute Urology on the Beach meeting.

Sudha Jayaraman, MD, MSc, FACS, recaps a session from the 2026 Urology on the Beach meeting focused on AI in health care.

Lina Posada Calderon, MD, discusses the background and key takeaways from her team’s study examining germline BAP1-associated renal cell carcinoma.

Alam frames PHI and MRI as noninvasive tools that help refine risk before proceeding to biopsy.

Despite improvements, Kalyani Narra, MD, highlights persistent gaps in referral among eligible patients.

John P. Sfakianos, MD, outlines the scientific rationale for combining systemic immunotherapy with BCG in the BCG-naïve NMIBC setting.

Wesley Hauwei Chou, MD, outlined 2 projects evaluating potential biomarkers for treatment response in renal cell carcinoma.

When symptoms appear tied to the menstrual cycle, pharmacologic options can be used as short-term support.

Iman Sadri, MD, CM, discusses a somatic-autonomic nerve grafting technique for patients with persistent erectile dysfunction after radical prostatectomy.

The session emphasized how rapidly evolving AI technologies are addressing long-standing inefficiencies in urologic care.

Walter R. Hsiang, MD, MBA, highlights a study looking at access to care, insurance acceptance, wait times, and costs for stone disease management.

Aleece Fosnight, MSPAS, PA-C, highlights pattern recognition as a cornerstone of diagnosis, encouraging clinicians to closely examine how urinary symptoms fluctuate across the menstrual cycle.

A key finding was that among the qualities applicants highlighted, only “learning and growth” correlated with interview selection.

Maxwell L. Sandberg, MD, highlights a study on survival outcomes between patients who underwent CN-TT via an open, laparoscopic, or robotic approach.

Notable findings highlighted stark differences between this safety-net population and national averages.

Fed Ghali, MD, discusses the phase 2 CONSOLIdaTE-01 trial, assessing the role for consolidative local therapy following disease control on EV/P.

Jennifer Miles-Thomas, MD, URPS, MBA, emphasizes that teleurology and team-based care models offer significant promise

Mark D. Tyson, II, MD, MPH, highlights interim findings from the ADVANCED-2 trial of TARA-002 in BCG-naïve NMIBC.

The study retrospectively analyzed 456 biopsy-naive men who underwent PHI testing followed by a prostate biopsy.

In the final installment in a 5-part series, Richard Wassersug, PhD, and Paul F. Schellhammer, MD, FACS, discuss strategies for establishing transdermal estradiol as a recognized therapy for men undergoing androgen deprivation therapy for prostate cancer.

In part 4 of a 5-part series, Richard Wassersug, PhD, and Paul F. Schellhammer, MD, FACS, focus on concerns about the adverse events of transdermal estradiol, particularly gynecomastia.